Eggermont Loek J, Paulis Leonie E, Tel Jurjen, Figdor Carl G
Department of Tumor Immunology, Radboud University Medical Centre and Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Department of Tumor Immunology, Radboud University Medical Centre and Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Trends Biotechnol. 2014 Sep;32(9):456-65. doi: 10.1016/j.tibtech.2014.06.007. Epub 2014 Jul 3.
Active anti-cancer immune responses depend on efficient presentation of tumor antigens and co-stimulatory signals by antigen-presenting cells (APCs). Therapy with autologous natural APCs is costly and time-consuming and results in variable outcomes in clinical trials. Therefore, development of artificial APCs (aAPCs) has attracted significant interest as an alternative. We discuss the characteristics of various types of acellular aAPCs, and their clinical potential in cancer immunotherapy. The size, shape, and ligand mobility of aAPCs and their presentation of different immunological signals can all have significant effects on cytotoxic T cell activation. Novel optimized aAPCs, combining carefully tuned properties, may lead to efficient immunomodulation and improved clinical responses in cancer immunotherapy.
有效的抗癌免疫反应依赖于抗原呈递细胞（APC）对肿瘤抗原的高效呈递和共刺激信号。自体天然APC治疗成本高昂且耗时，在临床试验中结果不一。因此，人工APC（aAPC）的开发作为一种替代方案引起了广泛关注。我们讨论了各种类型的无细胞aAPC的特性及其在癌症免疫治疗中的临床潜力。aAPC的大小、形状、配体流动性及其对不同免疫信号的呈递都会对细胞毒性T细胞的激活产生重大影响。结合精心调整特性的新型优化aAPC可能会在癌症免疫治疗中实现有效的免疫调节并改善临床反应。
